EXO Biologics, a clinical-stage biotech company based in Liège, Belgium, has secured €16 million in Series A funding to advance its pioneering work with exosomes for therapeutic use. The funding includes €9 million from investors such as Noshaq, Founders, and Belgian Family Offices, with an additional €7 million in subsidies